目的:探讨黄芪建中汤联合PPI三联法治疗幽门螺杆菌性消化性溃疡的临床疗效及安全性。方法:将符合纳入标准的66例幽门螺杆菌性消化性溃疡作为研究对象,随机分为治疗组与对照组,每组各33例,对照组为常规PPI三联疗法治疗,治疗组在对照组基础上联合黄芪建中汤治疗,连续治疗2个月后观察两组患者临床疗效、胃镜溃疡疗效、Hp清除率及不良反应等指标。结果:疗程结束后,治疗组临床总有效率(87.9%)明显高于对照组(78.8%),且胃镜治疗组总有效率(84.8%)显著优于对照组(75.8%),差异均有统计学意义(P<0.05);治疗组患者Hp根除率(87.9%)明显高于对照组(75.8%),而其不良反应发生率却低于对照组,差异均有统计学意义(P<0.05)。结论:黄芪建中汤联合PPI三联疗法治疗幽门螺杆菌性消化性溃疡的临床疗效确切,不良反应少,安全性好。 Objective: To investigate the clinical efficacy and safety of Huangqi Jianzhong Decoction combined with PPI triple therapy in the treatment of Helicobacter pylori peptic ulcer. Methods: A total of 66 cases of Helicobacter pylori peptic ulcer which met the inclusion criteria were randomly divided into treatment group and control group, with 33 cases in each group. The control group was treated with conventional PPI triple therapy. The treatment group was basal in the control group Combined with Astragalus Jianzhong decoction treatment, continuous treatment for 2 months after the two groups were observed clinical efficacy, efficacy of gastric ulcer, Hp clearance rate and adverse reactions and other indicators. Results: After treatment, the total effective rate (87.9%) in the treatment group was significantly higher than that in the control group (78.8%), and the total effective rate (84.8%) in the gastroscope group was significantly better than that in the control group (75.8%) (P <0.05). The Hp eradication rate (87.9%) in the treatment group was significantly higher than that in the control group (75.8%), while the incidence of adverse reactions was lower than that in the control group (P < 0.05). Conclusion: Astragalus Jianzhong Decoction combined with PPI triple therapy for the treatment of Helicobacter pylori peptic ulcer clinical efficacy, less adverse reactions, good safety.